Back to Journals » International Journal of Nanomedicine » Volume 17

Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer [Corrigendum]

Authors Ren S , Song L, Tian Y, Zhu L, Guo K, Zhang H, Wang Z 

Received 9 February 2022

Accepted for publication 9 February 2022

Published 16 February 2022 Volume 2022:17 Pages 711—712

DOI https://doi.org/10.2147/IJN.S361728



Ren S, Song L, Tian Y, et al. Int J Nanomedicine. 2021;16:7463–7478.

Page 7466, Cell Viability Assay and Apoptosis Analyses section, 3rd sentence, the text “Next, different concentrations of Fe3O4-PEG and Fe3O4-PEG-Cy7-EMO (0, 12.5, 25, 50, 80, 100 μg/mL) were added to the plates and incubated for 24 hours” should read “Next, different concentrations of Fe3O4-PEG and Fe3O4-PEG-Cy7-EMO (0, 6, 12, 25, 50, 80, 100 μg/mL) were added to the plates and incubated for 48 hours”.

Page 7473, Table 1, the value “62.23%” in the BxPC-3 row for the Fe3O4-PEG-Cy7-EMO (80µg/mL) column should read “62.63%”.

Page 7474, Figure 7A, due to an error at the time of figure assembly, the images for spleen and lung in the second and the third rows are identical. The correct Figure 7 is shown in Download Article.

The authors apologize for these errors and advise they do not affect the results of the paper.

Read the original article

Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.